Reckitt Ups 2018 Guidance On Mucinex 'All-In-One,' China Platform Gains
This article was originally published in The Pink Sheet & The Rose Sheet
Executive Summary
Max Cold & Flu All-In-One is the first Mucinex product providing an “all-in-one-and-done proposition" and is expected to offset the impact of private label products. Mucinex plus growth and expansion plans for infant formula spark increase in firm’s 2018 forecast.
You may also be interested in...
Perrigo ANDA Approval Brings New Options To Generic Mucinex DM Maximum Strength Portfolio
Perrigo's first OTC drug approved in 2018 is extended-relief guaifenesin 1,200 mg and dextromethorphan 60 mg tablets, planned for launch under its own store brand, Goodsense, as well as distribution for retailer and private label brands. It already distributes the product for store and private label brands through an agreement with Teva.
Reckitt At '2.0' On Consumer Expansion But Question No. 1 Remains, Potential Pfizer Business Bid?
UK firm sees acquisitions of Mead Johnson Nutrition and the Schiff brand as major milestones in its trajectory as a consumer health market competitor, but market analysts say both would be rendered comparatively minor moves if it makes an offer to acquire Pfizer's consumer products business.
Reckitt At '2.0' On Nutrition Market Expansion But Question No. 1 Remains, Potential Pfizer Consumer Bid?
UK firm sees acquisitions of Mead Johnson Nutrition and the Schiff brand as major milestones in its trajectory as a consumer health market competitor, but market analysts say both would be rendered comparatively minor moves if it makes an offer to acquire Pfizer's consumer products business. Mead Johnson's Enfamil NeuroPro infant formula line extension formulated with "milk fat globule membrane" and DHA should be available in US in March or April.